ArticleEJHaem2025
Nivolumab Induces Durable Remission in Relapsed/Refractory ALK-Negative ALCL After Allogeneic Blood Stem Cell Transplantation-A Case Report and Literature Review.
Article in EJHaem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Relapsed or refractory anaplastic large cell lymphoma (r/r-ALCL) remains an important therapeutic challenge, especially after allogeneic stem cell transplantation (alloHSCT). Due to encouraging results in other lymphoid diseases, PD-1 blockade was investigated in T-cell lymphoma in a small number of patients, but short duration of remission and significant adverse events were observed. Case Report: Here, we report successful and durable remission induction for more than 2 years with nivolumab for r/r-ALCL even without any evidence of PD-L1 expression. Conclusion: This report and literature review emphasizes the importance of the graft-versus-lymphoma effect and its potential pharmacological stimulators in the field of lymphoma treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.